Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

25 oct. 2022 06h00 HE | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Expands Research Collaboration with The Rockefeller University to Investigate Clinical-Stage Immuno-Dermatology Agent PH-10 for Skin Inflammation

KNOXVILLE, TN, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has expanded its sponsored research program with James G. Krueger, MD, PhD, Co-director,...
30 nov. 2017 06h00 HE | Source: Provectus Biopharmaceuticals Inc.

PROVECTUS ANNOUNCES RESULTS FROM MECHANISM OF ACTION STUDY OF TOPICAL PH-10 FOR THE TREATMENT OF PSORIASIS

– Responses mediated by multiple pathways, including IL-17, IL-22 and interferons – – Down-regulation of more than 500 disease-related genes; wide range of central “psoriasis-related” genes...